Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a price target of ...

智通财经APP获悉，GSK(GSK.US)日前宣布，美国FDA已授予其PD-1抑制剂Jemperli(dostarlimab)用于治疗局部晚期错配修复缺陷(dMMR)/高微卫星不稳定性(MSI-H)直肠癌的突破性疗法认定(BTD)。这是dostarl ...

▎药明康德内容团队编辑GSK日前宣布，美国FDA已授予其PD-1抑制剂Jemperli（dostarlimab）用于治疗局部晚期错配修复缺陷（dMMR）/高微卫星不稳定性（MSI-H）直肠癌的突破性疗法认定（BTD）。根据新闻稿，这是dostarli ...

AnaptysBio's rosnilimab faces significant competition and uncertainty. See why ANAB stock's future hinges on Feb 2025 Phase ...

GSK plc’s GSK HIV subsidiary, ViiV Healthcare announced that the Europe Medicines Agency’s (“EMA”) Committee for Medicinal ...

GSK (GSK) announced the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has recommended expanding the approval of Jemperli in combination with chemotherapy ...

GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for ...

US FDA grants breakthrough therapy designation to GSK’s Jemperli for locally advanced dMMR/MSI-H rectal cancer: London, UK Tuesday, December 17, 2024, 09:00 Hrs [IST] GSK plc an ...

Standard Investments, which owns 11% of the FTSE 250 firm, urged the board to launch a strategic review to look at 'a sale of ...

The FDA granted breakthrough therapy designation to dostarlimab for locally advanced dMMR/MSI-H rectal cancer, highlighting ...

在日本，GSK的呼吸道合胞病毒（RSV）疫苗Arexvy已获批用于50-59岁成年人。公司还报告了linerixibat的第三阶段GLISTEN试验的积极结果，该药物旨在治疗原发性胆汁性胆管炎患者的胆汁淤积性瘙痒。然而，由于预期2025年增长将趋于平缓，Jefferies和Guggenheim的金融分析师已下调了GSK的股票评级。

Jemperli是一种抗PD-1抗体，是GSK免疫肿瘤学研究和开发的基础。它目前在美国获批用于某些类型的子宫内膜癌，并在加速批准下用于dMMR复发或晚期实体瘤，继续批准取决于确证性试验的验证。本报告基于GSK plc的新闻稿。